πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,153 results for β€œOu” Clear

  1. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  2. -, RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to BehΓ§et’s syndrome

    phase 2 small molecule active

    1 trial

  3. 0.2mg group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opioid Dependence

    phase 2 small molecule active

    1 trial

  4. 0.9% Sodium Chloride for Injection (Fresenius Kab) sourced locally by sites, AP-101

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  5. 0.9% sodium chloride aqueous solution for IV infusion

    Chiesi Farmaceutici S.p.A

    Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  6. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  7. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  8. 30% Nitrous oxide

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial

  9. 3D hypoxia-preconditioned UC-MSC group

    The First People's Hospital of Lianyungang

    Severe Aplastic Anemia (SAA)

    phase 2 small molecule active

    1 trial

  10. 400 Β΅g of MBX 2109 once-weekly by subcutaneous injection

    MBX Biosciences

    Hypoparathyroidism

    phase 2 small molecule active

    1 trial

  11. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  12. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial

  13. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  14. 68Ga-FAPI-46

    Istituto Gentili S.r.l.

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  15. A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  16. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extensionβ€”assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic Ξ²-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  17. A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  18. A Clinical Trial for Patients with Advanced Cancers

    Corbus Pharmaceuticals Holdings

    Advanced Solid tumour

    phase 2 other active

    1 trial

  19. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

    Takeda

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

  20. A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  21. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  22. A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  23. A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial

  24. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources